Objective: To evaluate the clinical utility of urinary b-2-microglobulin (B2M) at birth, an alternative to proinflammatory cytokines, as an indicative marker of fetal inflammatory response and subsequent higher risk of bronchopulmonary dysplasia (BPD) in premature infants.
Introduction
Accumulating evidence has shown that inflammation has a key role in the etiology of preterm birth and its consequences on neonatal outcomes. [1] [2] [3] [4] The term 'fetal inflammatory response syndrome' describes the strong association between elevated levels of proinflammatory cytokines in the umbilical cord plasma, as well as increased neonatal morbidity and mortality. 5 Bronchopulmonary dysplasia (BPD) is a representative example of the pathophysiology among premature infants born to mothers with chorioamnionitis (CAM). Elevated inflammatory mediators such as interleukin-6, interleukin-8 and tumor necrosis factor-in the umbilical cord plasma or amniotic fluid have already been reported to be sensitive indicators of CAM and independent risk factors for the development of BPD. 4, 6 However, a direct assay of proinflammatory cytokines, which is both expensive and time consuming, is not suitable for routine laboratory testing in neonatal intensive care practice.
b-2-Microglobulin (B2M) has been proposed as a surrogate marker of inflammatory response, as it is expressed on the surface of most nucleated cells as a subunit of the class I major histocompatibility complex (MHC) and is upregulated by systemic immuneactivation. 7, 8 Elevated B2M levels in the serum and urine have been shown to be a nonspecific but sensitive indicator of various conditions, including infectious, lymphoproliferative, autoimmune and chronic inflammatory disorders. [7] [8] [9] [10] [11] Moreover, its potential role in perinatal medicine is particularly appealing because B2M does not cross the placenta. [12] [13] [14] In this study, we examined urinary levels of B2M at birth in premature infants, and assessed whether B2M levels can be used as an indicative marker of fetal inflammatory response and subsequent adverse pulmonary outcomes.
Methods

Study design
We examined the relationship between urinary excretion levels of B2M at birth and the occurrence of BPD in preterm (24 to 28 weeks) singleton neonates, who were admitted to the neonatal intensive care unit at the Japanese Red Cross Katsushika Maternity Hospital between January 2000 and December 2008. Neonates with major congenital anomalies, culture-positive sepsis with onset before 24 h of age and failure of urine sample to be obtained within 48 h of birth were excluded. Among these preterm infants, those administered postnatal steroids and indomethacin before collection of urine samples were also excluded. A total of 106 preterm infants were enrolled, and informed consent was obtained from the family members of each infant. This study was approved by the Institutional Review Board of our hospital.
Urinary B2M
Spontaneously voided urine samples were obtained using urine collection bags or by squeezing urine from cotton balls placed in diapers. All pathological samples showing proteinuria, hematuria, bacteriuria or abnormal sediments were excluded. Urine samples were used only when the pH level was >5.5, as B2M is known to be unstable in acid urine. Urinary B2M levels were assayed by latex agglutination reaction and corrected against urine creatinine values.
Diagnosis of BPD and other neonatal morbidities
Bronchopulmonary dysplasia was defined as a state of chronic oxygen requirement at 36 weeks postmenstrual age, plus a total oxygen duration of >28 days with chest radiographic findings of persistent hazy opacification or a cyst-like pattern of density and lucency, which corresponds to the moderate plus severe-grade BPD of NIH (National Institutes of Health) workshop consensus definition. 15 Mechanical ventilation was regarded as either intermittent mandatory or high-frequency oscillating mode under tracheal intubation on the day of birth. Patent ductus arteriosus was diagnosed by echocardiography, and only symptomatic cases indicated for pharmacological or surgical closure were identified. All placentas in the study population were histopathologically examined, and CAM was diagnosed based on polymorphonuclear leukocyte infiltration into the fetal membranes: subchorion, chorion or amnion.
Statistical analysis
Univariate analysis was conducted by Mann-Whitney's U-test, Student's t-test or Fisher's exact test. The relationship between urinary B2M at birth and gestational age was analyzed using Pearson's correlation test. A receiver-operating characteristic curve was constructed to select the cutoff value at which to consider urinary B2M at birth as being elevated. Logistic regression analysis was used to examine the relationship between elevated urinary B2M levels and the occurrence of BPD, controlling for the effect of potential confounding variables. A P-value of <0.05 was considered to be significant.
Results
A total of 106 premature infants had a urinary B2M measurement within 48 h of birth. Of these, 10 were excluded from further analyses: 6 infants died before 36-weeks postmenstrual age and 4 were transferred from our hospital for surgery during the neonatal period. A total of 96 neonates were thus eligible for this study. There were no significant differences between the final study population and the 10 excluded infants with regard to gestational age, receipt of mechanical ventilation on the day of birth and antenatal glucocorticoid treatment, occurrence of CAM and preterm premature rupture of the membranes beyond 24 h, cord pH and lactate. The median urinary B2M (10 4 mg per gCr) level of the study population was 14.5 (range: 0.9 to 45.4). The level was not significantly different from that of the 10 excluded infants (median B2M 13.1 (range: 0.3 to 31.9)).
Bronchopulmonary dysplasia was diagnosed in 34% (33/96) of the infants in the current study at 36-weeks postmenstrual age. Table 1 compares the clinical characteristics of the study population according to the development of BPD. Infants with BPD had a significantly lower gestational age, birth weight and a higher occurrence rate of histological CAM than did those without BPD. Otherwise, there were no significant differences in clinical profiles. Figure 1 shows a scatter plot of urinary B2M level at birth by gestational age coded according to the development of BPD. The urinary B2M levels were greater at any gestational age in neonates with BPD than in those without BPD. However, there was no significant correlation between urinary B2M level and gestational age in the patient group with BPD (r ¼ À0.157, P ¼ 0.382). Figure 2 illustrates urinary B2M levels at birth according to the development of BPD. Neonates with BPD had a significantly greater median B2M than did those without BPD (P<0.0001).
A receiver-operating characteristic curve was constructed to select the cutoff value at which to consider urinary B2M levels at Role of B2M as an alternative inflammatory marker Y Shima et al birth as being elevated for the development of BPD. We selected a cutoff value of 19.6 (10 4 mg per gCr), in which the receiveroperating characteristic curve shows a sharp deviation (Figure 3 ; area under the curve, 0.800; s.e., 0.049; P<0.0001). Urinary B2M at birth of >19.6 (10 4 mg per gCr) had a sensitivity of 73% (24/33), a specificity of 83% (52/63), a positive predictive value of 69% (24/35) and a negative predictive value of 85% (52/61). After we adjusted for the effects of gestational age, elevated urinary B2M at birth significantly increased the odds of BPD development (odds ratio, 11.1; 95% confidence interval, 4.1 to 32.7; P<0.0001). The relationship remained significant (odds ratio, 10.4; 95% confidence interval, 3.7 to 32.4; P<0.0001) even after adjustment for other variables that were significantly associated with the occurrence of BPD according to univariate analysis (Table 1) .
Histological CAM was verified in 43% (41/96) of the study population. According to placental pathology, the median urinary B2M levels at birth were significantly greater in neonates whose mothers had CAM than in neonates whose mothers did not (P<0.001) (Figure 4 ). Antenatal glucocorticoid treatment was performed on 33 fetuses in total: 18 of complete course and 15 of partial. There was no significant difference in urinary B2M levels at birth between neonates who received antenatal glucocorticoid treatment and those who did not. Role of B2M as an alternative inflammatory marker Y Shima et al
Discussion
Our results indicate that the presence of both neonatal BPD and maternal CAM was associated with significantly greater levels of urinary B2M at birth.
A number of studies have demonstrated a strong association between the development of BPD and antenatal inflammation, as indicated by placental pathology, and increased levels of proinflammatory cytokines such as interleukin-6, interleukin-8 and tumor necrosis factor-a, in the umbilical cord blood or amniotic fluid. [4] [5] [6] In this study, we focused on urinary excretion of B2M obtained from premature infants at birth as an alternative inflammatory marker, because a routine measurement of these cytokines in such clinical specimens is not yet feasible.
b-2-Microglobulin is a low-molecular-weight protein that is present on the surface of most nucleated cells, including lymphocytes and macrophages, as part of the class I MHC. 8, 16 In inflamed tissues, there is an increased expression of MHC and other inducible genes reflecting the production of cytokines. 17 Moreover, localized inflammation induces large changes in MHC mRNA and product expression at many remote and otherwise unaffected sites, involving parenchymal and interstitial cells in many vital organs. 18 As B2M is mainly produced by lymphocytes as a component of MHC, its serum levels reflect the state of lymphocyte activation. For that reason, increased serum B2M levels have been used as a useful marker of systemic inflammation. 7 With regard to urinary B2M, increased levels are seen in two situations: when serum concentrations exceed the tubular reabsorption threshold and in proximal tubular dysfunction, as B2M freely passes through the glomerulus and is almost completely reabsorbed at the renal proximal tubules. 19 During the inflammatory response, both overproduction of serum B2M by immuneactivation and impaired renal reabsorption due to proximal tubular injury would occur simultaneously. These combined effects could augment the urinary excretion of B2M to excess levels, particularly among premature infants whose renal tubular systems are susceptible to various types of insult during both prenatal and early postnatal periods.
In this study, no neonates whose urine output was <0.5 ml kg À1 per h during the first 48 h of age or whose serum creatinine level was >1.0 mg per 100 ml were included. Therefore, the elevated urinary B2M observed in this study was probably not due to decreased glomerular filtration, but rather largely due to the synergic effects between overproduction in the blood and impaired reabsorption caused by tubular dysfunction during the inflammatory process.
It has also been reported that although both serum and urine B2M levels are considerably elevated during inflammation, urinary concentrations are a particularly sensitive marker in assessing disease activity of lymphoactivated conditions. 10, 20 In this study, elevated levels of neonatal urinary B2M at birth were correlated with development of BPD, as well as with the presence of CAM, thus suggesting that inflammatory processes beginning before birth are responsible for subsequent adverse pulmonary outcomes. We have previously demonstrated the elevation of urinary B2M in premature infants with CAM and chronic lung disease, defined as an oxygen requirement for X28 days. 11 In this study, the cohort was expanded with more immature patients and also limited only with the moderate and more grade of BPD based on diagnostic criteria of the NIH workshop consensus, as to see longer-term outcome. 15 Still, we have confirmed that urinary B2M level at birth could be a useful indicator for the later development of BPD. The correlation between the level of urinary B2M and the severity of BPD was not observed.
The maturational change in proximal tubular reabsorption rate should be considered because urinary B2M has been used as an index of renal function. In our data, higher levels of B2M at birth were observed in neonates with BPD than in those without BPD at any gestational age. In addition, no correlation was found between the urinary B2M level at birth and gestational age in neonates with BPD. These findings suggest that elevation of urinary B2M at birth in neonates with BPD was not simply caused by prematurity but mainly by the influence of intrauterine inflammatory response. Moreover, the association between elevated B2M levels and the development of BPD remained significant, even after adjustment for gestational weeks at birth and other confounding factors in this study.
Antenatal exposure to inflammation evokes the production of excess proinflammatory cytokines, which in turn leads to organ damage resulting in long-term adverse outcomes. 5 This series of events, described as fetal inflammatory response syndrome, was originally defined as elevated levels of proinflammatory cytokines in the umbilical cord plasma. The advantages of measuring B2M, instead of proinflammatory cytokines, are the lower cost and ready availability for routine laboratory testing. Moreover, urine sample collection could be used as a traceable indicator for evaluating perinatal inflammatory response, because it is simpler and safer than cordocentesis, amniocentesis or bronchoalveolar lavage fluid.
Despite the fact that the pathogenesis of BPD is uncertain and multifactorial, inflammation before birth certainly has a key role. As the fetal inflammatory response syndrome is characterized by systemic activation of the fetal immune system, elevated urinary B2M levels at birth reflect both the intensity of the inflammatory response and the degree of tubular damage, which may indicate the clinical situation more precisely than cytokine measurement alone.
It is an important issue in the care of premature infants to forecast a risk of BPD in the early stage. Although measurement of urinary B2M is an indirect assessment, a noninvasive approach for evaluating the level of inflammatory response would be beneficial. Therefore, we propose this simple marker as an additional tool for evaluation of the fetal inflammatory response and subsequent risk of BPD.
Conclusion
Elevated urinary B2M levels at birth may be a timely indicator of fetal inflammatory response and subsequent BPD risk. Defining the physiological mechanisms that are responsible for higher urine levels of B2M at birth and that lead to BPD, and developing strategies that safely and effectively modify this pathophysiology, will improve outcomes for preterm infants.
